

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
3 January 2003 (03.01.2003)

PCT

(10) International Publication Number
WO 03/000675 A1(51) International Patent Classification⁷: C07D 311/68,
A61K 31/353, A61P 9/06

(21) International Application Number: PCT/JP02/06012

(22) International Filing Date: 17 June 2002 (17.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2001-190594 25 June 2001 (25.06.2001) JP(71) Applicant (for all designated States except US): NISSAN
CHEMICAL INDUSTRIES, LTD. [JP/JP]; 7-1, Kandan-
ishiki-cho 3-chome, Chiyoda-ku, Tokyo 101-0054 (JP).

(72) Inventors; and



(75) Inventors/Applicants (for US only): OHARA, Yoshio
[JP/JP]; c/o Nissan Chemical Industries, Ltd. Chemical
Research Laboratories, 722-1, Tsuboi-cho, Funabashi-shi,
Chiba 274-8507 (JP). OHRAI, Kazuhiko [JP/JP]; c/o
Nissan Chemical Industries, Ltd. Chemical Research
Laboratories, 722-1, Tsuboi-cho, Funabashi-shi, Chiba
274-8507 (JP). YANAGIHARA, Kazufumi [JP/JP]; c/o
Nissan Chemical Industries, Ltd. Chemical Research
Laboratories, 722-1, Tsuboi-cho, Funabashi-shi, Chiba
274-8507 (JP). SHIGETA, Yukihiro [JP/JP]; c/o Nissan
Chemical Industries, Ltd. Chemical Research Laborato-
ries, 722-1, Tsuboi-cho, Funabashi-shi, Chiba 274-8507
(JP). TSUKAGOSHI, Toru [JP/JP]; c/o Nissan Chem-
ical Industries, Ltd. Chemical Research Laboratories,722-1, Tsuboi-cho, Funabashi-shi, Chiba 274-8507 (JP).
YAMASHITA, Toru [JP/JP]; c/o Nissan Chemical Indus-
tries, Ltd. Biological Research Laboratories, 1470, Oaza
Shiraoka, Shiraoka-machi, Minamisaitama-gun, Saitama
349-0294 (JP).(74) Agents: HANABUSA, Tsuneo et al.; c/o Hanabusa Patent
Office, Sin-ochanomizu Urban Trinity, 2, Kandasurugadai
3-chome, Chiyoda-ku, Tokyo 101-0062 (JP).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZM, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED BENZOPYRAN DERIVATIVES AGAINST ARRHYTHMIA

(57) Abstract: This invention relates to benzopy-
ran derivatives of the formula (1) or the formula
(2) wherein R¹ and R² represent independently of
each other hydrogen atom or C₁₋₆alkyl group, R³
represents hydroxyl group or C₁₋₆alkylcarbony-
loxy group, R⁴ represents hydrogen atom or C₁₋₆
alkyl group, R⁵ represents C₁₋₆ alkyl group sub-
stituted with C₆₋₁₄ aryl group or heteroaryl group,
R⁶ represents C₁₋₆ alkyl group, C₁₋₆ alkoxy group,
halogen atom, nitro group, C(O)NH₂, C(O)NHR⁸or C(O)NR⁸R⁹, or pharmaceutically acceptable salts thereof. These compounds are useful as an antiarrhythmic agent.

WO 03/000675 A1

DESCRIPTION

SUBSTITUTED BENZOPYRAN DERIVATIVES AGAINST ARRHYTHMIA

Technical Field

The present invention relates to substituted benzopyran derivatives having the prolongation effect on the refractory period used for the treatment of arrhythmia in mammals including human being.

Background Art

As benzopyran derivatives, 4-acylaminobenzopyran derivatives exemplified by Cromakalim (Jananese Patent Application Laid-open No. Sho 58-67683) have been known. These 4-acylaminobenzopyran derivatives exemplified by Cromakalim are known to open ATP sensitive K⁺ channel so as to be effective for the treatment of hypertension and asthma, but there has not been any mention as to the treatment of arrhythmia based on the prolongation effect on the refractory period.

At present, conventional anti-arrhythmic agents having the prolongation effect on the refractory period as a main mechanism (such as Class I drugs of antiarrhythmic agent classification according to Vaughan Williams, or d-sotalol belonging to Class III) have been the therapeutic problems in inducing highly dangerous arrhythmia leading to the sudden death from such as *torsades de pointes* among others due to prolongation of action potential in ventricular muscle correlated to the prolongation effect on the refractory period. Thus, treating agents with less adverse effect have been highly desired.


Disclosure of Invention

The inventors of the present invention have investigated compounds having the prolongation effect on the refractory period selective for atrium muscle rather than for ventricular muscle, and found that the compound of the formula (1) or the formula (2) has the prolongation effect on the refractory period selective for atrium muscle without any influence on the refractory period and action potential in ventricular muscle.

The inventors of the present invention have eagerly investigated benzopyran derivatives, and found that the compound of the formula (1) or the formula (2) has the strong prolongation effect on the refractory period to be useful as an

antiarrhythmic agent to their delight. Thus, the present invention has been accomplished.

The present invention relates to a benzopyran derivative of the formula (1) or the formula (2)



wherein

R^1 and R^2 represent independently of each other hydrogen atom or C_{1-6} alkyl group (wherein said alkyl group may be optionally substituted with halogen atom, C_{1-6} alkoxy group or hydroxyl group);

R^3 represents hydroxyl group or C_{1-6} alkylcarbonyloxy group;

R^4 represents hydrogen atom or C_{1-6} alkyl group;

R^5 represents C_{1-6} alkyl group substituted with C_{6-14} aryl group or heteroaryl group [wherein said C_{1-6} alkyl group may be optionally substituted with hydroxyl group, methyl group, and said C_{6-14} aryl group or heteroaryl group may be optionally substituted with 1 to 3 R^7 (wherein R^7 may be optionally substituted with halogen atom, nitro group, cyano group, hydroxyl group, formyl group, formamide group, amino group, C_{1-6} alkyl group, C_{1-6} alkoxy group (wherein said C_{1-6} alkyl group, C_{1-6} alkoxy group may be optionally substituted with halogen atom), C_{3-6} cycloalkyl group, C_{1-6} alkylamino group, di- C_{1-6} alkylamino group, C_{1-6} alkylcarbonylamino group, C_{1-6} alkylsulfonylamino group, aminocarbonyl group, C_{1-6} alkylaminocarbonyl group, di- C_{1-6} alkylaminocarbonyl group, C_{1-6} alkylcarbonyl group, C_{1-6} alkoxycarbonyl group, aminosulfonyl group, C_{1-6} alkylsulfonyl group, carboxyl group or benzoyl group (wherein said benzoyl group may be optionally substituted with C_{1-6} alkyl group, C_{1-6} alkoxy group, halogen atom, nitro group or cyano group))] or straight-chain C_{5-8} alkyl group (wherein said C_{5-8} alkyl group may be optionally substituted with fluorine atom or hydroxyl group);

R^6 represents C_{1-6} alkyl group (wherein said alkyl group may be optionally substituted with hydroxyl group, carboxyl group, amino group, C_{1-6} alkylamino group,

di- C_{1-6} alkylamino group, $C(O)OR^8$, $NHSO_2R^8$, $C(O)NH_2$, $C(O)NHR^8$ or $C(O)NR^8R^9$ (wherein R^8 and R^9 represent independently of each other C_{1-6} alkyl group substituted with C_{6-14} aryl group or heteroaryl group or C_{1-6} alkyl group)), C_{1-6} alkoxy group, halogen atom, nitro group, $C(O)NH_2$, $C(O)NHR^8$ or $C(O)NR^8R^9$ (wherein R^8 and R^9 represent independently of each other C_{1-6} alkyl group substituted with C_{6-14} aryl group or heteroaryl group or C_{1-6} alkyl group)];
or a pharmaceutically acceptable salt thereof.

The compound according to the present invention has the strong prolongation effect on the refractory period and it can be used as a drug for treating arrhythmia.

Respective substituents for the compound (1) according to the present invention are concretely defined below.

Furthermore, "n" means normal, "i" means iso, "s" means secondary, "t" means tertiary, "c" means cyclo, "o" means ortho, "m" means meta and "p" means para in this specification.

Examples of C_{1-6} alkyl group are such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, 1-pentyl, 2-pentyl, 3-pentyl, i-pentyl, neopentyl, 2,2-dimethylpropyl, 1-hexyl, 2-hexyl, 3-hexyl, 1-methyl-n-pentyl, 1,1,2-trimethyl-n-propyl, 1,2,2-trimethyl-n-propyl, 3,3-dimethyl-n-butyl, trifluoromethyl, trifluoroethyl, pentafluoroethyl, cyanomethyl, hydroxymethyl and the like.

Preferably, methyl, ethyl, n-propyl, i-propyl and n-butyl may be mentioned.

Examples of halogen atom are such as fluorine atom, chlorine atom, bromine atom and iodine atom. Preferably, fluorine atom, chlorine atom and bromine atom may be mentioned.

Examples of C_{1-6} alkoxy group are such as methoxy, trifluoromethoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy, t-butoxy, 1-pentyloxy, 2-pentyloxy, 3-pentyloxy, i-pentyloxy, neopentyloxy, 2, 2-dimethylpropoxy, 1-hexyloxy, 2-hexyloxy, 3-hexyloxy, 1-methyl-n-pentyloxy, 1, 1, 2-trimethyl-n-propoxy, 1, 2, 2-trimethyl-n-propoxy, 3, 3-dimethyl-n-butoxy and the like.

Preferably, methoxy, ethoxy, n-propoxy and i-propoxy may be mentioned.

Examples of C₁₋₆ alkylcarbonyloxy group are such as methylcarbonyloxy, ethylcarbonyloxy, n-propylcarbonyloxy, i-propylcarbonyloxy, n-butylcarbonyloxy, i-butylcarbonyloxy, s-butylcarbonyloxy, t-butylcarbonyloxy, 1-pentylcarbonyloxy, 2-pentylcarbonyloxy, 3-pentylcarbonyloxy, i-pentylcarbonyloxy, neopentylcarbonyloxy, t-pentylcarbonyloxy, 1-hexylcarbonyloxy, 2-hexylcarbonyloxy, 3-hexylcarbonyloxy, 1-methyl-n-pentylcarbonyloxy, 1, 1, 2-trimethyl-n-propylcarbonyloxy, 1, 2, 2-trimethyl-n-propylcarbonyloxy, 3, 3-dimethyl-n-butylcarbonyloxy and the like.

Preferably, methylcarbonyloxy, ethylcarbonyloxy, n-propylcarbonyloxy, i-propylcarbonyloxy, n-butylcarbonyloxy and t-butylcarbonyloxy may be mentioned.

Examples of C₆₋₁₄ aryl group are such as phenyl, biphenyl, naphthyl, anthryl, phenanthryl and the like.

Preferably, phenyl may be mentioned.

Examples of heteroaryl group are such as 2-thienyl group, 3-thienyl group, 2-furyl group, 3-furyl group, 2-pyranyl group, 3-pyranyl group, 4-pyranyl group, 2-benzofuranyl group, 3-benzofuranyl group, 4-benzofuranyl group, 5-benzofuranyl group, 6-benzofuranyl group, 7-benzofuranyl group, 1-isobenzofuranyl group, 4-isobenzofuranyl group, 5-isobenzofuranyl group, 2-benzothienyl group, 3-benzothienyl group, 4-benzothienyl group, 5-benzothienyl group, 6-benzothienyl group, 7-benzothienyl group, 1-isobenzothienyl group, 4-isobenzothienyl group, 5-isobenzothienyl group, 2-chromenyl group, 3-chromenyl group, 4-chromenyl group, 5-chromenyl group, 6-chromenyl group, 7-chromenyl group, 8-chromenyl group, 1-pyrrolyl group, 2-pyrrolyl group, 3-pyrrolyl group, 1-imidazolyl group, 2-imidazolyl group, 4-imidazolyl group, 1-pyrazolyl group, 3-pyrazolyl group, 4-pyrazolyl group, 2-thiazolyl group, 4-thiazolyl group, 5-thiazolyl group, 3-isothiazolyl group, 4-isothiazolyl group, 5-isothiazolyl group, 2-oxazolyl group, 4-oxazolyl group, 5-oxazolyl group, 3-isooxazolyl group, 4-isooxazolyl group, 5-isooxazolyl group, 2-pyridyl group, 3-pyridyl group, 4-pyridyl group, 2-pyridinyl group, 2-pyrimidinyl group, 4-pyrimidinyl group, 5-pyrimidinyl group, 3-pyridazinyl group, 4-pyridazinyl group, 1-indoliziny group, 2-indoliziny group, 3-indoliziny group, 5-indoliziny group, 6-indoliziny group, 7-indoliziny group, 8-indoliziny group, 1-isoindolyl group, 4-isoindolyl group, 5-isoindolyl group, 1-indolyl group, 2-indolyl group, 3-indolyl group, 4-indolyl group, 5-indolyl group, 6-indolyl group, 7-indolyl group, 1-indazolyl group,

2-indazolyl group, 3-indazolyl group, 4-indazolyl group, 5-indazolyl group, 6-indazolyl group, 7-indazolyl group, 2-quinolyl group, 3-quinolyl group, 4-quinolyl group, 5-quinolyl group, 6-quinolyl group, 7-quinolyl group, 8-quinolyl group, 1-isoquinolyl group, 3-isoquinolyl group, 4-isoquinolyl group, 5-isoquinolyl group, 6-isoquinolyl group, 7-isoquinolyl group, 8-isoquinolyl group, 1-phthalazinyl group, 5-phthalazinyl group, 6-phthalazinyl group, 2-naphthyridinyl group, 3-naphthyridinyl group, 4-naphthyridinyl group, 2-quinoxaliny group, 5-quinoxaliny group, 6-quinoxaliny group, 2-quinazolinyl group, 4-quinazolinyl group, 5-quinazolinyl group, 6-quinazolinyl group, 7-quinazolinyl group, 8-quinazolinyl group and the like.

Preferably, 2-pyridyl group, 3-pyridyl group and 4-pyridyl group may be mentioned.

Examples of C_{3-6} cycloalkyl group are such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.

Preferably, cyclopropyl, cyclobutyl and cyclohexyl may be mentioned.

Examples of C_{1-6} alkylamino group are such as methylamino, ethylamino, n-propylamino, i-propylamino, c-propylamino, n-butylamino, i-butylamino, s-butylamino, t-butylamino, c-butylamino, 1-pentylamino, 2-pentylamino, 3-pentylamino, i-pentylamino, neopentylamino, t-pentylamino, c-pentylamino, 1-hexylamino, 2-hexylamino, 3-hexylamino, c-hexylamino, 1-methyl-n-pentylamino, 1,1,2-trimethyl-n-propylamino, 1,2,2-trimethyl-n-propylamino, 3,3-dimethyl-n-butylamino and the like.

Preferably, methylamino, ethylamino, n-propylamino, i-propylamino and n-butylamino may be mentioned.

Examples of di- C_{1-6} alkylamino group are such as dimethylamino, diethylamino, di-n-propylamino, di-i-propylamino, di-c-propylamino, di-n-butylamino, di-i-butylamino, di-s-butylamino, di-t-butylamino, di-c-butylamino, di-1-pentylamino, di-2-pentylamino, di-3-pentylamino, di-i-pentylamino, di-neopentylamino, di-t-pentylamino, di-c-pentylamino, di-1-hexylamino, di-2-hexylamino, di-3-hexylamino, di-c-hexylamino, di-(1-methyl-n-pentyl)amino, di-(1,1,2-trimethyl-n-propyl)amino, di-(1,2,2-trimethyl-n-propyl)amino, di-(3,3-dimethyl-n-butyl)amino, methyl(ethyl)amino, methyl(n-propyl)amino, methyl(i-propyl)amino, methyl(c-propyl)amino, methyl(n-butyl)amino, methyl(i-butyl)amino, methyl(s-butyl)amino, methyl(t-butyl)amino, methyl(c-butyl)amino, ethyl(n-propyl)amino, ethyl(i-propyl)amino, ethyl(c-

propyl)amino, ethyl(n-butyl)amino, ethyl(i-butyl)amino, ethyl(s-butyl)amino, ethyl(t-butyl)amino, ethyl(c-butyl)amino, n-propyl(i-propyl)amino, n-propyl(c-propyl)amino, n-propyl(n-butyl)amino, n-propyl(i-butyl)amino, n-propyl(s-butyl)amino, n-propyl(t-butyl)amino, n-propyl(c-butyl)amino, i-propyl(c-propyl)amino, i-propyl(n-butyl)amino, i-propyl(i-butyl)amino, i-propyl(s-butyl)amino, i-propyl(t-butyl)amino, i-propyl(c-butyl)amino, c-propyl(n-butyl)amino, c-propyl(i-butyl)amino, c-propyl(s-butyl)amino, c-propyl(t-butyl)amino, c-propyl(c-butyl)amino, n-butyl(i-butyl)amino, n-butyl(s-butyl)amino, n-butyl(t-butyl)amino, n-butyl(c-butyl)amino, i-butyl(s-butyl)amino, i-butyl(t-butyl)amino, i-butyl(c-butyl)amino, s-butyl(t-butyl)amino, s-butyl(c-butyl)amino, t-butyl(c-butyl)amino and the like.

Preferably, dimethylamino, diethylamino, di-n-propylamino, di-i-propylamino and di-n-butylamino may be mentioned.

Examples of C₁₋₆ alkylcarbonylamino group are such as methylcarbonylamino, ethylcarbonylamino, n-propylcarbonylamino, i-propylcarbonylamino, n-butylcarbonylamino, i-butylcarbonylamino, s-butylcarbonylamino, t-butylcarbonylamino, 1-pentylcarbonylamino, 2-pentylcarbonylamino, 3-pentylcarbonylamino, i-pentylcarbonylamino, neopentylcarbonylamino, t-pentylcarbonylamino, 1-hexylcarbonylamino, 2-hexylcarbonylamino, 3-hexylcarbonylamino and the like.

Preferably, methylcarbonylamino, ethylcarbonylamino, n-propylcarbonylamino, i-propylcarbonylamino and n-butylcarbonylamino may be mentioned.

Examples of C₁₋₆ alkylsulfonylamino group are such as methylsulfonylamino, ethylsulfonylamino, n-propylsulfonylamino, i-propylsulfonylamino, n-butylsulfonylamino, i-butylsulfonylamino, s-butylsulfonylamino, t-butylsulfonylamino, 1-pentylsulfonylamino, 2-pentylsulfonylamino, 3-pentylsulfonylamino, i-pentylsulfonylamino, neopentylsulfonylamino, t-pentylsulfonylamino, 1-hexylsulfonylamino, 2-hexylsulfonylamino, 3-hexylsulfonylamino and the like.

Preferably, methylsulfonylamino, ethylsulfonylamino, n-propylsulfonylamino, i-propylsulfonylamino and n-butylsulfonylamino may be mentioned.

Examples of C₁₋₆ alkylaminocarbonyl group are such as methylaminocarbonyl, ethylaminocarbonyl, n-propylaminocarbonyl, i-propyl-

aminocarbonyl, n-butylaminocarbonyl, i-butylaminocarbonyl, s-butylaminocarbonyl, t-butylaminocarbonyl, 1-pentylaminocarbonyl, 2-pentylaminocarbonyl, 3-pentylaminocarbonyl, i-pentylaminocarbonyl, neopentylaminocarbonyl, t-pentylaminocarbonyl, 1-hexylaminocarbonyl, 2-hexylaminocarbonyl, 3-hexylaminocarbonyl and the like.

Preferably, methylaminocarbonyl, ethylaminocarbonyl, n-propylaminocarbonyl, i-propylaminocarbonyl and n-butylaminocarbonyl may be mentioned.

Examples of di-C₁₋₆ alkylaminocarbonyl group are such as dimethylaminocarbonyl, diethylaminocarbonyl, di-n-propylaminocarbonyl, di-i-propylaminocarbonyl, di-c-propylaminocarbonyl, di-n-butylaminocarbonyl, di-i-butylaminocarbonyl, di-s-butylaminocarbonyl, di-t-butylaminocarbonyl, di-c-butylaminocarbonyl, di-1-pentylaminocarbonyl, di-2-pentylaminocarbonyl, di-3-pentylaminocarbonyl, di-i-pentylaminocarbonyl, di-neopentylaminocarbonyl, di-t-pentylaminocarbonyl, di-c-pentylaminocarbonyl, di-1-hexylaminocarbonyl, di-2-hexylaminocarbonyl, di-3-hexylaminocarbonyl and the like.

Preferably, dimethylaminocarbonyl, diethylaminocarbonyl, di-n-propylaminocarbonyl, di-i-propylaminocarbonyl, di-c-propylaminocarbonyl and di-n-butylaminocarbonyl may be mentioned.

Examples of C₁₋₆ alkylcarbonyl group are such as methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, i-propylcarbonyl, n-butylcarbonyl, i-butylcarbonyl, s-butylcarbonyl, t-butylcarbonyl, 1-pentylcarbonyl, 2-pentylcarbonyl, 3-pentylcarbonyl, i-pentylcarbonyl, neopentylcarbonyl, t-pentylcarbonyl, 1-hexylcarbonyl, 2-hexylcarbonyl, 3-hexylcarbonyl and the like.

Preferably, methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, i-propylcarbonyl and n-butylcarbonyl may be mentioned.

Examples of C₁₋₆ alkoxy carbonyl group are such as methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, i-propoxycarbonyl, n-butoxycarbonyl, i-butoxycarbonyl, s-butoxycarbonyl, t-butoxycarbonyl, 1-pentyloxycarbonyl, 2-pentyloxycarbonyl, 3-pentyloxycarbonyl, i-pentyloxycarbonyl, neopentyloxy carbonyl, t-pentyloxycarbonyl, 1-hexyloxycarbonyl, 2-hexyloxycarbonyl, 3-hexyloxycarbonyl and the like.

Preferably, methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, i-propoxycarbonyl, n-butoxycarbonyl, i-butoxycarbonyl, s-butoxycarbonyl and t-butoxycarbonyl may be mentioned.

Examples of C₁₋₆ alkylsulfonyl group are such as methanesulfonyl, ethanesulfonyl and the like.

Examples of straight-chain C₅₋₈ alkyl group are such as n-pentyl group, 5-hydroxy-n-pentyl group, 5-trifluoro-n-pentyl group, n-hexyl group, 6-hydroxy-n-hexyl group, 6-trifluoro-n-hexyl group, n-heptyl group, n-octyl group and the like.


Preferably, n-pentyl group, n-hexyl group may be mentioned.

As preferable compounds used in the present invention, the following compounds may be mentioned.

- (1) The benzopyran derivative of the formula (1) or the formula (2), or the pharmaceutically acceptable salt thereof, wherein both R¹ and R² represent methyl group, R³ represents a hydroxyl group and R⁴ represents hydrogen atom.
- (2) The benzopyran derivative or the pharmaceutically acceptable salt thereof described in (1) above, wherein R⁵ represents C₁₋₆ alkyl group substituted with C₆₋₁₄ aryl group.
- (3) The benzopyran derivative or the pharmaceutically acceptable salt thereof described in (2) above, wherein R⁶ represents nitro group.
- (4) The benzopyran derivative of the formula (2) or the pharmaceutically acceptable salt thereof described in (3) above.
- (5) The benzopyran derivative or the pharmaceutically acceptable salt thereof described in (2) above, wherein R⁶ represents C(O)NH₂.
- (6) The benzopyran derivative or the pharmaceutically acceptable salt thereof described in (2) above, wherein R⁶ represents methyl group.


Concrete examples of the compounds that can be used in the present invention are shown below, but the present invention is not limited thereto. In addition, "Me" means methyl group, "Et" means ethyl group, "Pr" means propyl group, "Bu" means butyl group, "Pen" means pentyl group, "Hex" means hexyl group, "Ph" means phenyl group, "o" means "ortho", "m" means "meta" and "p" means "para", respectively.

Table 1



R^1	R^2	R^3	R^4	n
H	H	OH	H	0
Me	Me	OH	Me	1
Me	Me	OH	Et	2
Me	Me	OH	n-Pr	3
Me	Me	OH	i-Pr	4
Me	Me	OH	n-Bu	0
Me	Me	OH	i-Bu	1
Me	Me	OH	t-Bu	2
Me	Me	OH	n-Pen	3
Me	Me	OH	n-Hex	4
Me	Me	OH	H	2
Me	Me	OH	Me	2
Me	Me	OH	Et	3
Me	Me	OCOMe	H	2
Me	Me	OCOEt	H	2
Me	Me	OH	H	1
Me	Me	OH	H	2
Me	Me	OH	H	3
Me	Me	OH	H	4
Et	Et	OH	H	2
n-Pr	n-Pr	OH	H	2
i-Pr	i-Pr	OH	H	2
n-Bu	n-Bu	OH	H	2
i-Bu	i-Bu	OH	H	2
t-Bu	t-Bu	OH	H	3
n-Pen	n-Pen	OH	H	3
n-Hex	n-Hex	OH	H	3
CF_3	CF_3	OH	H	3
CH_2OCH_3	CH_2OCH_3	OH	H	3

Table 2




R ¹	R ²	R ³	R ⁴	n
H	H	OH	H	0
Me	Me	OH	Me	1
Me	Me	OH	Et	2
Me	Me	OH	n-Pr	3
Me	Me	OH	i-Pr	4
Me	Me	OH	n-Bu	0
Me	Me	OH	i-Bu	1
Me	Me	OH	t-Bu	2
Me	Me	OH	n-Pen	3
Me	Me	OH	n-Hex	4
Me	Me	OH	H	2
Me	Me	OH	Me	2
Me	Me	OH	Et	3
Me	Me	OCOMe	H	2
Me	Me	OCOEt	H	2
Me	Me	OH	H	1
Me	Me	OH	H	2
Me	Me	OH	H	3
Me	Me	OH	H	4
Et	Et	OH	H	2
n-Pr	n-Pr	OH	H	2
i-Pr	i-Pr	OH	H	2
n-Bu	n-Bu	OH	H	2
i-Bu	i-Bu	OH	H	2
t-Bu	t-Bu	OH	H	3
n-Pen	n-Pen	OH	H	3
n-Hex	n-Hex	OH	H	3
CF ₃	CF ₃	OH	H	3
CH ₂ OCH ₃	CH ₂ OCH ₃	OH	H	3

Table 3


<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;"> </div> <div style="text-align: center;"> </div> </div>				
R ¹	R ²	R ³	R ⁴	n
H	H	OH	H	0
Me	Me	OH	Me	1
Me	Me	OH	Et	2
Me	Me	OH	n-Pr	3
Me	Me	OH	i-Pr	4
Me	Me	OH	n-Bu	0
Me	Me	OH	i-Bu	1
Me	Me	OH	t-Bu	2
Me	Me	OH	n-Pen	3
Me	Me	OH	n-Hex	4
Me	Me	OH	H	2
Me	Me	OH	Me	2
Me	Me	OH	Et	3
Me	Me	OCOMe	H	2
Me	Me	OCOEt	H	2
Me	Me	OH	H	1
Me	Me	OH	H	2
Me	Me	OH	H	3
Me	Me	OH	H	4
Et	Et	OH	H	2
n-Pr	n-Pr	OH	H	2
i-Pr	i-Pr	OH	H	2
n-Bu	n-Bu	OH	H	2
i-Bu	i-Bu	OH	H	2
t-Bu	t-Bu	OH	H	3
n-Pen	n-Pen	OH	H	3
n-Hex	n-Hex	OH	H	3
CF ₃	CF ₃	OH	H	3
CH ₂ OCH ₃	CH ₂ OCH ₃	OH	H	3

Table 4



R ³	R ⁴	R ⁶
OH	H	Me
OH	Me	Et
OH	Et	n-Pr
OH	n-Pr	n-Bu
OH	i-Pr	t-Bu
OH	n-Bu	n-Pen
OH	i-Bu	n-Hex
OH	t-Bu	CH ₂ OH
OH	n-Pen	CH ₂ NH ₂
OH	n-Hex	CH ₂ NHMe
OH	H	CH ₂ NMe ₂
OH	Me	CH ₂ COOEt
OH	Et	CH ₂ CONH ₂
OCOMe	H	MeO
OCOEt	H	EtO
OH	H	Cl
OH	H	F
OH	H	Br
OH	H	NO ₂
OH	H	CONH ₂
OH	H	CONHMe
OH	H	CONMe ₂
OH	H	Me
OH	H	CONH ₂
OH	H	CONH ₂
OH	H	CONH ₂
OH	H	CONH ₂
OH	H	CONH ₂
OH	H	CONH ₂

Table 5



R^3	R^7
OH	p-F
OH	p-Cl
OH	p-Br
OH	m-F
OH	m-Cl
OH	o-F
OH	o-Cl
OH	p-NO ₂
OH	p-CN
OH	p-OH
OH	m-OH
OH	o-OH
OH	p-CHO
OCOMe	p-CONH ₂
OCOEt	p-NH ₂
OH	p-F
OH	p-OMe
OH	o-OMe
OH	p-cHex
OH	p-NHMe
OH	p-NMe ₂
OH	p-NHCOMe
OH	p-COMe
OH	p-F
OH	p-Cl
OH	m-F
OH	m-Cl
OH	o-F
OH	o-Cl

The compound according to the present invention has asymmetric carbon atoms at 3-position and 4-position, thus optical isomers thereof based on the asymmetric carbon atoms are present, and optical active substances can be also used in the application of the present invention, like racemic modifications. Further, cis- and trans-isomer based on configuration at 3-position and 4-position may be included, but trans-isomer is preferred.

Further, when the compounds can form their salts, the pharmaceutically acceptable salts thereof can also be used as active ingredients.


Examples of pharmaceutically acceptable salt are such as hydrochlorides, hydrobromides, sulfates, methanesulfonates, acetates, benzoates, tartrates, phosphates, lactates, maleates, fumarates, malates, gluconates, salicylates and the like.

Preferably, hydrochlorides, methanesulfonates and maleates may be mentioned.

The method of preparation of the compound according to the present invention is illustrated.

The compound of the formula (1) or the formula (2) can be obtained by reacting compound of the formula (3) or the formula (4) with the compound (5) in an inert solvent as shown in the reaction scheme described below.

The compound of the formula (3) or the formula (4) can be synthesized according to known methods (methods described in J. M. Evans *et al.*, J. Med. Chem. 1984, 27, 1127; J. Med. Chem. 1986, 29, 2194; J. T. North *et al.*, J. Org. Chem. 1995, 60, 3397; as well as Jananese Patent Application Laid-open No. Sho 56-57785, Jananese Patent Application Laid-open No. Sho 56-57786, Jananese Patent Application Laid-open No. Sho 58-188880, Jananese Patent Application Laid-open No. Hei 2-141, Jananese Patent Application Laid-open No. Hei 10-87650 and Jananese Patent Application Laid-open No. Hei 11-209366 and the like.).



As the solvents used in the reaction of the compound of the formula (3) or the formula (4) with the compound (5), the following may be mentioned.

Sulfoxide type solvents exemplified by dimethylsulfoxide; amide type solvents exemplified by dimethylformamide or dimethylacetamide; ether type solvents exemplified by ethylether, dimethoxyethane or tetrahydrofuran; halogen type solvents exemplified by dichloromethane, chloroform and dichloroethane; nitrile type solvents exemplified by acetonitrile and propionitrile; aromatic hydrocarbon type solvents exemplified by benzene and toluene; hydrocarbon type solvents exemplified by hexane and heptane; and ester type solvents exemplified by ethyl acetate may be mentioned. Further, the reaction can be carried out in the absence of any solvent. Preferably, ether type solvents and nitrile type solvents may be mentioned.

The reaction temperature is generally from -80°C to the reflux temperature of the reaction solvent, preferably from -10°C to 100°C .

The molar ratio of the reaction materials is within the range of 0.5-20.0, preferably 1.0-10.0, for the compound (5)/the compound (3) or the compound (5)/the compound (4).

An acid catalyst may be used in the reaction.


Examples of the acid catalysts used are such as inorganic acids exemplified

by hydrochloric acid and sulfuric acid, and Lewis acids exemplified by aluminum chloride, titanium tetrachloride, boron trifluoride diethyl ether complex, perchloric acid, lithium perchlorate, lithium bromide and ytterbium trifluoromethanesulfonate and the like may be mentioned.

Preferably, lithium bromide, perchloric acid and lithium perchlorate may be mentioned.

The compounds of the formula (2) can be obtained upon diazotization of the compound of the formula (6) followed by reductive deamination reaction as shown in the reaction scheme described below (the method described in Jananese Patent Application Laid-open No. Sho 52-91866).

The compounds of the formula (6) can be synthesized according to known methods (methods described in J. M. Evans *et al.*, J. Med. Chem. 1984, 27, 1127; J. Med. Chem. 1986, 29, 2194; as well as Jananese Patent Application Laid-open No. Sho 56-57785, Jananese Patent Application Laid-open No. Sho 56-57786, Jananese Patent Application Laid-open No. Sho 58-188880, Jananese Patent Application Laid-open No. Hei 2-141, Jananese Patent Application Laid-open No. Hei 10-87650 and Jananese Patent Application Laid-open No. Hei 11-209366, Jananese Patent Application Laid-open No. 2001-151767 and the like.).



Examples of acid to be used in diazotization are such as hydrochloric acid, sulfuric acid and the like.

Examples of reducing agent to be used in reductive deamination reaction of diazonium salt are such as alcohol exemplified by methanol and ethanol, hypophosphorous acid, sodium borohydride and the like, but preferred is hypophosphorous acid.

Syntheses of optically active compounds among the compounds of the

formula (1) or the formula (2) can be attained by utilizing optical resolution methods (Jananese Patent Application Laid-open No. Hei 3-141286, U.S. Patent No. 5,097,037 and European Patent No. 409,165).

Furthermore, syntheses of optically active compounds of the formula (3) or the formula (4) can be attained by utilizing asymmetric synthetic methods (Jananese National Publication No. Hei 5-507645, Jananese Patent Application Laid-open No. Hei 5-301878, Jananese Patent Application Laid-open No. Hei 7-285983, European Patent Laid-open No.535377 and U.S. Patent No. 5420314).

As described above, the inventors of the present invention found that the compound of the formula (1) or the formula (2) has the strong prolongation effect on the refractory period. The prolongation effect on the refractory period is one of mechanisms of anti-arrhythmic action and is an important indicator that can be taken in judging the effectiveness in clinical arrhythmia. Conventional anti-arrhythmic agents having the prolongation effect on the refractory period as the main mechanism (such as d-sotalol belonging to Class III of the antiarrhythmic agent classification according to Vaughan Williams) have been the therapeutic problems in inducing highly dangerous arrhythmia leading to the sudden death from such as *torsades de pointes* among others due to prolongation of action potential in ventricular muscle correlated to the prolongation effect on the refractory period, and thus becoming the therapeutic problem in arrhythmia mainly of atrial muscle (such as supraventricular tachycardia, atrial flutter, atrial fibrillation and the like).

In order to solve the problems, the inventors of the present invention carried out the investigation of compounds having the prolongation effect on the refractory period selective for atrium muscle than for ventricular muscle, and found that the compound of the formula (1) or the formula (2) has the prolongation effect on the refractory period selective for atrium muscle without any influence on the refractory period and action potential in ventricular muscle. The difference between the findings by the inventors of the present invention and the prior art is in providing the prolongation effect on the refractory period selective for atrium muscle to these compound group, which may be shown by the facts that there is no influence on the action potential duration period of isolated ventricular muscle and there is no influence on QT in the electrocardiogram of anesthetized animal. From above, the compounds of the present invention show no inducing action of arrhythmia in

ventricular muscle, thus they can contribute to much safer use in arrhythmia mainly of atrial muscle in comparison with the prior art. The present technical knowledge is beneficial for therapeutic or preventive uses as anti-atrial fibrillation agents, anti-atrial flutter agents and anti-atrial tachycardia agents relating to paroxysmal, chronic, preoperative, intraoperative or postoperative atrial arrhythmia, prevention in the progression leading to embolus due to arrhythmia of atrial nature, prevention in the progression leading to ventricular arrhythmia or tachycardia from atrial arrhythmia or tachycardia, and averting the life threatening prognosis due to preventive action on atrial arrhythmia or tachycardia leading to ventricular arrhythmia or tachycardia.

The present invention provides a pharmaceutical composition or a veterinary pharmaceutical composition containing a compound of the formula (1) or the formula (2) in an effective amount for these treatments.

As forms of administration for the compound according to the present invention, parenteral administration forms such as injections (subcutaneous, intravenous, intramuscular and intraperitoneal injections), ointments, suppositories, aerosols and the like, and oral administration forms such as tablets, capsules, granules, pills, syrups, solutions, emulsions, suspensions and the like can be mentioned.

The pharmaceutical or veterinary pharmaceutical composition described above contains the compound according to the present invention in an amount of about 0.01-99.5%, preferably about 0.1-30%, based on the total weight of the composition.

In addition to the compound according to the present invention or the composition containing the compound, other pharmaceutically or veterinary pharmaceutically active compounds may be contained.

Further, these compositions may contain the plurality of compounds according to the present invention.

An amount of the compound according to the present invention to be used in clinical administration may vary depending on age, weight and sensitivity of the patient, symptomatic condition and the like, but an effective amount in clinical

administration is generally about 0.003-1.5 g, preferably 0.01-0.6 g, per day for adult. If necessary, however, the amount outside of the aforementioned range may be used.

The compound according to the present invention is formulated for administration by conventional pharmaceutical means.

That is, tablets, capsules, granules and pills for oral administration are prepared by using excipients such as sucrose, lactose, glucose, starch and mannitol; binders such as hydroxypropyl cellulose, syrup, gum arabic, gelatin, sorbitol, tragacanth, methyl cellulose and polyvinyl pyrrolidone; disintegrators such as starch, carboxymethyl cellulose or its calcium salt, microcrystalline cellulose and polyethylene glycol; lubricants such as talc, magnesium or calcium stearate, and silica; lubricating agents such as sodium laurate and glycerol and the like.

Injections, solutions, emulsions, suspensions, syrups and aerosols are prepared by using solvents for the active components such as water, ethyl alcohol, isopropyl alcohol, propylene glycol, 1,3-butylene glycol and polyethylene glycol; surfactants such as sorbitan fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyoxyethylene ether of hydrogenated castor oil and lecithin; suspending agents such as carboxymethyl sodium salt, cellulose derivatives such as methyl cellulose, tragacanth, and natural rubbers such as gum arabic; and preserves such as p-hydroxybenzoic acid esters, benzalkonium chloride and sorbic acid salts and the like.

For ointments that are transdermally adsorptive pharmaceuticals, for example, white vaseline, liquid paraffin, higher alcohols, Macrogol ointments, hydrophilic ointments, aqueous gel-type bases and the like are used.


Suppositories are prepared by using, for example, cocoa fats, polyethylene glycol, lanolin, fatty acid triglyceride, coconut oil, polysorbate and the like.

Best Mode for Carrying Out the Invention

The present invention is illustrated in detail by the Examples as follows, but the present invention is not limited to these Examples.

Furthermore, salen manganese complex means an optically active compound of the formula below which was synthesized according to the method

similar to one described in Jananese Patent Application Laid-open No. Hei 7-285983.




In addition, (3*R**, 4*S**)-6-amino-3, 4-dihydro-2, 2-dimethyl-7-nitro-4-(2'-phenethylamino)-2H-1-benzopyran-3-ol used as the raw material in Synthetic Example 6 was prepared by heating the compound synthesized according to the method described in Jananese Patent Application Laid-open No. 2001-151767 (Synthetic Example 72) in ethanol and 35% hydrochloric acid.

[Synthesis Examples]

Reference Synthesis Example 1

(3*R**, 4*R**)-6-cyano-3, 4-epoxy-3, 4-dihydro-2, 2-dimethyl-2H-1-benzopyran



To a solution (34 mL) of ethyl acetate containing 3.4 g (18 mmol) of 6-cyano-2, 2-dimethyl-2H-1-benzopyran (synthesized according to the method described in SYNTHEISIS, 1995, 707), salen manganese complex (0.56g, 0.54 mmol), 4-(3-phenylpropyl)-pyridineoxide) (0.42 g, 1.8 mmol) and aqueous sodium hypochlorite solution (21 g, 12.8 %wt., 36 mmol) were added at room temperature, and then stirred for one hour at room temperature. After Celite filtration upon addition of water, organic phase was separated, washed with aqueous saturated

sodium chloride solution, and dried over anhydride sodium sulfate. After distilling off the solvent, the residue was purified by silica gel column chromatography (hexane:acetone = 5:1), and then re-crystallized from ethyl acetate-hexane to obtain 2.05 g of the intended compound in light brown crystal (Yield 57%).

$^1\text{H-NMR}$ (CDCl_3) δ : 1.30 (s, 3H), 1.60 (s, 3H), 3.54 (d, $J=4.3$ Hz, 1H), 3.91 (d, $J=4.3$ Hz, 1H), 6.87 (d, $J=8.5$ Hz, 1H), 7.53 (dd, $J=1.9, 8.5$ Hz, 1H), 7.65 (d, $J=1.9$ Hz, 1H).


MS (EI) m/z : 145 (bp), 201

m.p. 145.3-146.6°C

$[\alpha]_D^{25}=74.7$ ($c=1.0$, CHCl_3)

Reference Synthesis Example 2

(3*R**, 4*R**)-3, 4-epoxy-6-ethyl-3, 4-dihydro-2, 2-dimethyl-2H-1-benzopyran




To a solution (2 mL) of ethyl acetate containing 100 mg (0.53 mmol) of 6-ethyl-2, 2-dimethyl-2H-1-benzopyran (synthesized according to the method described in Japanese Patent Application Laid-open No. Sho 62-273972), salen manganese complex (17 mg, 0.016 mmol), 4-(3-phenylpropyl)-pyridineoxide (12 mg, 0.053 mmol) and aqueous sodium hypochlorite solution (0.96 g, 1.14 Kg/mol, 1.1 mmol) were added at room temperature, and stirred for two hours at room temperature. After Celite filtration upon addition of water, organic phase was separated, washed with aqueous saturated sodium chloride solution, and dried over anhydride sodium sulfate. After distilling off the solvent, the residue was purified by silica gel column chromatography (chloroform) to obtain 75 mg of the intended compound in brown oily substance (Yield 69%).

$^1\text{H-NMR}$ (CDCl_3) δ : 1.21-1.24 (m, 6H), 1.57 (s, 3H), 2.54-2.59 (m, 2H), 3.47 (d, $J=4.4$ Hz, 1H), 3.87 (d, $J=4.4$ Hz, 1H), 6.72 (d, $J=8.2$ Hz, 1H), 7.66 (dd, $J=2.2, 8.2$ Hz, 1H), 7.20 (d, $J=2.2$ Hz, 1H).

Reference Synthesis Example 3

(3*R**, 4*R**)-3, 4-epoxy-3, 4-dihydro-6-methyl-2, 2-dimethyl-2H-1-benzopyran




¹H-NMR (CDCl₃) δ : 1.23 (s, 3H), 1.57 (s, 3H), 2.28 (s, 3H), 3.47 (d, *J*=4.4 Hz, 1H), 3.85 (d, *J*=4.4 Hz, 1H), 6.69-7.14 (m, 3H).

MS (EI) *m/z*: 135 (bp), 189 [M-1]⁺.

Reference Synthesis Example 4

(3*R**, 4*S**)-6-cyano-4-(2-phenylethylamino)-3, 4-dihydro-2, 2-dimethyl-2H-1-benzopyran-3-ol




To a solution (13 mL) of acetonitrile containing the compound synthesized in Reference Synthesis Example 1 (1.3 g, 6.5 mmol) and lithium perchlorate (2.8 g, 26 mmol), 2-phenylethyl amine (3.3 mL, 26 mmol) was added at room temperature and stirred for one hour at 65°C. Upon addition of ethyl acetate, organic phase was washed with water and aqueous saturated sodium chloride solution, and then dried over anhydride sodium sulfate. After distilling off the solvent, the residue was purified by silica gel column chromatography (hexane:ethyl acetate = 3:1) to obtain 1.88 g of the intended compound in brown oily substance (Yield 90%).

¹H-NMR (CDCl₃) δ : 1.18 (s, 3H), 1.49 (s, 3H), 2.76-2.97 (m, 5H), 3.50 (d, *J*=10.0 Hz, 1H), 3.63 (d, *J*=10.0 Hz, 1H), 6.81 (d, *J*=8.5 Hz, 1H), 7.22-7.41 (m, 7H).

MS (EI) *m/z*: 202 (bp), 323 [M+1]⁺.

Reference Synthesis Example 5

(3*R**, 4*S**)-6-cyano-4-[2-(4-fluorophenyl) ethylamino]-3, 4-dihydro-2, 2-dimethyl-2H-1-benzopyran-3-ol



The compound was synthesized using 2-(4-fluorophenyl) ethylamine according to the method similar to one described in Reference Synthesis Example 4.

Yield 91%


Brown oily substance

¹H-NMR (CDCl₃) δ : 1.19 (s, 3H), 1.50 (s, 3H), 2.74-2.94 (m, 5H), 3.51 (d, *J*=10.1 Hz, 1H), 3.64 (d, *J*=10.1 Hz, 1H), 6.82 (d, *J*=8.5 Hz, 1H), 7.01-7.07 (m, 2H), 7.16-7.21 (m, 2H), 7.36-7.42 (m, 2H).

MS (EI) *m/z*: 109, 132 (bp), 269, 340 [*M*]⁺.

Reference Synthesis Example 6

(3*R**, 4*S**)-6-cyano-4-[2-(2-fluorophenyl) ethylamino]-3, 4-dihydro-2, 2-dimethyl-2H-1-benzopyran-3-ol



The compound was synthesized using 2-(2-fluorophenyl) ethylamine according to the method similar to one described in Reference Synthesis Example 4.

Yield 73%


Brown oily substance

$^1\text{H-NMR}$ (CDCl_3) δ : 1.18 (s, 3H), 1.49 (s, 3H), 2.74-2.94 (m, 5H), 3.50 (d, $J=10.0$ Hz, 1H), 3.64 (d, $J=10.0$ Hz, 1H), 6.81 (d, $J=8.5$ Hz, 1H), 7.01-7.41 (m, 6H).

MS (EI) m/z : 109, 160 (bp), 268, 341 $[\text{M}+1]^+$.

Synthesis Example 1

(3*R**, 4*S**)-4-[2-(4-chlorophenyl) ethylamino]-6-ethyl-3, 4-dihydro-2, 2-dimethyl-2H-1-benzopyran-3-ol




To a solution (0.30 mL) of acetonitrile containing the compound synthesized in Reference Synthesis Example 2 (59 mg, 0.29 mmol) and lithium perchlorate (0.38 g, 1.2 mmol), 2-(4-chlorophenyl) ethylamine (0.21 mL, 1.2 mmol) was added at room temperature and stirred for two hours at 65°C. Upon addition of ethyl acetate, organic phase was washed with water and aqueous saturated sodium chloride solution, and then dried over anhydride sodium sulfate. After distilling off the solvent, the residue was purified by silica gel column chromatography (chloroform:ethyl acetate = 5:1) to obtain 36 mg of the intended compound in brown solid (Yield 34%).

$^1\text{H-NMR}$ (CDCl_3) δ : 1.15-1.20 (m, 6H), 1.47 (s, 3H), 2.51 (q, $J=7.7$ Hz, 2H), 2.77-2.84 (m, 4H), 3.52 (d, $J=10.0$ Hz, 1H), 3.62 (d, $J=10.0$ Hz, 1H), 6.68-7.30 (m, 7H).

MS (EI) m/z : 290 (bp), 341, 358 $[\text{M}-1]^+$.

Synthesis Example 2

(3*R**, 4*S**)-4-[2-(4-chlorophenyl) ethylamino]-3, 4-dihydro-6-methyl-2, 2-dimethyl-2H-1-benzopyran-3-ol



The compound was synthesized using the compound synthesized in Reference Synthesis Example 3 according to the method similar to one described in Synthesis Example 1.

Yield 60%

Colorless crystal


$^1\text{H-NMR}$ (CDCl_3) δ : 1.16 (s, 3H), 1.47 (s, 3H), 2.22 (s, 3H), 2.77-2.83 (m, 5H), 3.50-3.59 (m, 2H), 6.66-7.28 (m, 7H).

MS (FAB) m/z : 346 $[\text{M}]^+$ (bp).

m.p. 133-135°C

Synthesis Example 3

(3*R**, 4*S**)-6-carbamoyl-4-(2-phenylethylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol



To a solution (7.2 mL) of dimethylsulfide containing the compound synthesized in Reference Synthesis Example 4 (1.44 g, 4.47 mmol) under ice-cooling, 30% aqueous hydrogen peroxide solution (1.44 mL) and potassium carbonate (93 mg, 0.67 mmol) were added and then stirred for 30 minutes at room temperature. Upon addition of a small amount of water, and then saturated sodium hydrogen carbonate, extracted with ethyl acetate and dried over anhydride sodium sulfate. After distilling off the solvent, the residue was re-crystallized from ethyl

acetate-hexane solvent to obtain 1.28 g of the intended compound in colorless crystal (Yield 84%).


$^1\text{H-NMR}$ (DMSO-d_6) δ : 1.10 (s, 3H), 1.37 (s, 3H), 2.72-2.83 (m, 4H), 3.54 (dd, $J=5.2$, 9.1 Hz, 1H), 3.64 (d, $J=9.1$ Hz, 1H), 5.27 (d, $J=5.2$ Hz, 1H), 6.72 (d, $J=8.4$ Hz, 1H), 7.22-7.41 (m, 5H), 7.61 (dd, $J=1.9$, 8.4 Hz, 1H), 8.05 (d, $J=1.9$ Hz, 1H).

MS (EI) m/z : 267 (bp), 341 $[\text{M}+1]^+$.

m.p. 162.0-162.5°C

Synthesis Example 4

(3*R**, 4*S**)-6-carbamoyl-4-[2-(4-fluorophenyl) ethylamino]-3, 4-dihydro-2, 2-dimethyl-2H-1-benzopyran-3-ol



The compound was synthesized using the compound synthesized in Reference Synthesis Example 5 according to the method similar to one described in Synthesis Example 3.

Yield 79%

Colorless crystal


$^1\text{H-NMR}$ (DMSO-d_6) δ : 1.10 (s, 3H), 1.37 (s, 3H), 2.54-2.83 (m, 4H), 3.54 (dd, $J=5.1$, 8.9 Hz, 1H), 3.63 (d, $J=8.9$ Hz, 1H), 5.26 (d, $J=5.1$ Hz, 1H), 6.71 (d, $J=8.3$ Hz, 1H), 7.04-7.10 (m, 2H), 7.21-7.26 (m, 2H), 7.61 (dd, $J=2.2$, 8.3 Hz, 1H), 8.03 (d, $J=2.2$ Hz, 1H).

MS (EI) m/z : 177 (bp), 286, 358 $[\text{M}]^+$.

m.p. 186.5-189.3°C

Synthesis Example 5

(3*R**, 4*S**)-6-carbamoyl-4-[2-(4-fluorophenyl) ethylamino]-3, 4-dihydro-2, 2-dimethyl-2H-1-benzopyran-3-ol



The compound was synthesized using the compound synthesized in Reference Synthesis Example 6 according to the method similar to one described in Synthesis Example 3.

Yield 34%

Colorless crystal


$^1\text{H-NMR}$ (DMSO-d_6) δ : 1.10 (s, 3H), 1.36 (s, 3H), 2.20-2.80 (m, 4H), 3.54-3.63 (m, 2H), 5.27 (d, $J=5.2$ Hz, 1H), 6.71 (d, $J=8.5$ Hz, 1H), 7.07-7.29 (m, 4H), 7.61 (dd, $J=8.5$ Hz, 1H), 8.03 (s, 1H).

MS (EI) m/z : 286 (bp), 359 $[\text{M}+1]^+$.

m.p. 149.0-152.1°C

Synthesis Example 6

(3*R**, 4*S**)-3, 4-dihydro-2, 2-dimethyl-7-nitro-4-(2'-phenethylamino)-2H-1-benzopyran-3-ol maleate



To a mixed solution of acetic acid (135 mL) and 4mol/L hydrochloric acid (135 mL) containing (3*R**, 4*S**)-6-amino-3, 4-dihydro-2, 2-dimethyl-7-nitro-4-(2'-phenethylamino)-2H-1-benzopyran-3-ol (45 g, 125.9 mmol), aqueous sodium nitrite solution (8.69 g, 125.9 mmol, dissolved in 45 mL water) was dropwise added at -20°C over 30 minutes, followed by the dropwise addition of 50% phosphorous acid solution (225 mL). The temperature of the reaction solution was elevated to 0°C and stirred for one hour. The reaction mixture was made to alkaline (pH 12) with 10

mol/L aqueous sodium hydroxide solution, extracted with ethyl acetate, then organic phase was washed with 1mol/L aqueous sodium hydroxide, aqueous saturated ammonium chloride solution and aqueous saturated sodium chloride solution, and finally dried over anhydride sodium sulfate. After distilling off the solvent, the residue was purified by silica gel column chromatography (hexane:ethyl acetate = 5:1), the intended free type compound was obtained in brown oily substance. Next, an ethanol solution (172 mL) containing maleic acid (13.5 g, 115 mmol) was dropwise added into the ethanol solution (345 mL) containing the free type compound under reflux condition. The reaction solution was stirred for one hour at room temperature. The obtained crystal was filtered, washed with ethanol, dried to get the intended substance (41.3 g, 72% Yield).

Light yellow crystal, mp.; 201-202°C, $^1\text{H-NMR}$ (DMSO- d_6) δ : 1.15 (s, 3H), 1.47 (s, 3H), 2.87-3.05 (m, 3H), 3.23-3.26 (m, 1H), 3.35 (br.s, 1H), 3.97 (dd, $J=4.7$ and 9.0 Hz, 1H), 4.42 (d, $J=9.0$ Hz, 1H), 6.08 (s, 2H), 6.21 (br.s, 1H), 7.20-7.35 (m, 5H), 7.60 (s, 1H), 7.84 (s, 2H).

MS (EI) m/z ; 343 $[\text{M}+1]^+$, 105 (bp).

[Preparation Examples]

Preparation Example 1

Tablet:

a compound according to the invention	10g
lactose	260g
microcrystalline cellulose	600g
corn starch	350g
hydroxypropyl cellulose	100g
CMC-Ca	150g
magnesium stearate	30g
Total weight	1,500g

The aforementioned ingredients were mixed by a conventional method and then 10,000 sugar-coated tablets each containing 1 mg of the active ingredient per tablet were prepared.

Preparation Example 2

Capsule:

a compound according to the invention	10g
lactose	440g
microcrystalline cellulose	1,000g
magnesium stearate	50g
Total weight	1,500g

The aforementioned ingredients were mixed by a conventional method and then filled into gelatin capsules to prepare 10,000 capsules each containing 1 mg of the active ingredient per capsule.

Preparation Example 3

Soft capsule:

a compound according to the invention	10g
PEG 400	479g
saturated fatty acid triglyceride	1,500g
peppermint oil	1g
Polysorbate 80	10g
Total weight	2,000g

The aforementioned ingredients were mixed by a conventional method and then filled into No. 3 soft gelatin capsules to prepare 10,000 soft capsules each containing 1 mg of the active ingredient per capsule.

Preparation Example 4

Ointment:

a compound according to the invention	1.0g
liquid paraffin	10.0g
cetanol	20.0g
white vaseline	68.4g
ethylparaben	0.1g
1-menthol	0.5g
Total weight	100.0g

The aforementioned ingredients were mixed by a conventional method to obtain 1% ointment.

Preparation Example 5

Suppository:

a compound according to the invention	1g
Witepsol H15*	478g
Witepsol W35*	520g
Polysorbate 80	1g
Total weight	1,000g

(* trade name for triglyceride type compounds)

The aforementioned ingredients were melt-mixed by a conventional method, poured into suppository containers and cooled to solidify, and 1,000 suppositories (1g) each containing 1 mg of the active ingredient per suppository were prepared.

Preparation Example 6

Injection:

a compound according to the invention	1mg
distilled water for injection	5mL

It is used by dissolving when applied.

[Pharmacological Test Example]Effects on the effective refractory periodMethod

Beagles were anesthetized with pentobarbital sodium and thoracotomy was done along the median line under a respirator and the incision was made on the pericardium to expose the heart. ECG was recorded using bipolar electrodes attached to the surface of the right atrial free wall, right atrial auricle, and right ventricular free wall. The vagal nerves were stimulated using an electrostimulation device with Nichrome wires inserted into the vagal nerves in the neck bilaterally. The conditions for electrostimulation to the vagal nerves were set such that the RR intervals on ECG were prolonged by about 100msec compared with those before the stimulation was started.

Atrial and ventricular effective refractory periods were determined by S1-S2 extrastimulus technique at basic cycle length of 300 msec during bilateral vagal

nerve stimulation, using programmable electric stimulator. A train of 10 basic stimuli(S1) was followed by a premature extrastimulus(S2) at 2 times diastolic threshold. The S1-S2 interval was successively decreased by 2 msec, and the effective refractory period was defined as the point at which S2 failed to produced a propagated response.

For evaluation of drug effects, the atrial and ventricular effective refractory periods were determined before drug administration, then respective compound was administrated intravenously at the dose of 0.3 mg/kg, and the atrial and ventricular effective refractory periods were determined from 5 min after the administration.

The results were shown as the prolongation time on the atrial and ventricular effective refractory periods, i.e. [effective refractory period after drug administration] - [effective refractory period before drug administration] (msec).

Table 6:

compound (Synthesis Example No.)	prolongation time on the effective refractory period (msec)	
	Atrium	Ventricle
2	23	4
3	21	4
4	23	-10
5	19	3
6	36	9

Results


The compounds of the present invention showed the prolongation effect on the effective refractory period selective for atrium.

Effects of the invention


Compounds according to the present invention exhibit the prolongation effect on the effective refractory period selective for atrium, thus can be used as an anti-atrial fibrillation agents and an supraventricular antiarrhythmic agent, and are useful as pharmaceuticals. Further, since compounds according to the present invention have small influence on ventricle, they can contribute to safe treatments of aforementioned arrhythmic conditions.

CLAIMS

1. A benzopyran derivative of the formula (1) or the formula (2)



(1)



(2)

wherein

R¹ and R² represent independently of each other hydrogen atom or C₁₋₆ alkyl group (wherein said alkyl group may be optionally substituted with halogen atom, C₁₋₆ alkoxy group or hydroxyl group);

R³ represents hydroxyl group or C₁₋₆ alkylcarbonyloxy group;

R⁴ represents hydrogen atom or C₁₋₆ alkyl group;

R⁵ represents C₁₋₆ alkyl group substituted with C₆₋₁₄ aryl group or heteroaryl group [wherein said C₁₋₆ alkyl group may be optionally substituted with hydroxyl group, methyl group, and said C₆₋₁₄ aryl group or heteroaryl group may be optionally substituted with 1 to 3 R⁷ (wherein R⁷ may be optionally substituted with halogen atom, nitro group, cyano group, hydroxyl group, formyl group, formamide group, amino group, C₁₋₆ alkyl group, C₁₋₆ alkoxy group (wherein said C₁₋₆ alkyl group, C₁₋₆ alkoxy group may be optionally substituted with halogen atom), C₃₋₆ cycloalkyl group, C₁₋₆ alkylamino group, di-C₁₋₆ alkylamino group, C₁₋₆ alkylcarbonylamino group, C₁₋₆ alkylsulfonylamino group, aminocarbonyl group, C₁₋₆ alkylaminocarbonyl group, di-C₁₋₆ alkylaminocarbonyl group, C₁₋₆ alkylcarbonyl group, C₁₋₆ alkoxycarbonyl group, aminosulfonyl group, C₁₋₆ alkylsulfonyl group, carboxyl group or benzoyl group (wherein said benzoyl group may be optionally substituted with C₁₋₆ alkyl group, C₁₋₆ alkoxy group, halogen atom, nitro group or cyano group))] or straight-chain C₅₋₈ alkyl group (wherein said C₅₋₈ alkyl group may be optionally substituted with fluorine atom or hydroxyl group);

R⁶ represents C₁₋₆ alkyl group (wherein said alkyl group may be optionally substituted with hydroxyl group, carboxyl group, amino group, C₁₋₆ alkylamino group,

di- C_{1-6} alkylamino group, $C(O)OR^8$, $NHSO_2R^8$, $C(O)NH_2$, $C(O)NHR^8$ or $C(O)NR^8R^9$ (wherein R^8 and R^9 represent independently of each other C_{1-6} alkyl group substituted with C_{6-14} aryl group or heteroaryl group or C_{1-6} alkyl group)), C_{1-6} alkoxy group, halogen atom, nitro group, $C(O)NH_2$, $C(O)NHR^8$ or $C(O)NR^8R^9$ (wherein R^8 and R^9 represent independently of each other C_{1-6} alkyl group substituted with C_{6-14} aryl group or heteroaryl group or C_{1-6} alkyl group));
or a pharmaceutically acceptable salt thereof.

2. The benzopyran derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein both R^1 and R^2 represent methyl group, R^3 represents hydroxyl group and R^4 represents hydrogen atom.

3. The benzopyran derivative or pharmaceutically acceptable salt thereof according to claim 2, wherein R^5 represents C_{1-6} alkyl group substituted with C_{6-14} aryl group..

4. The benzopyran derivative or pharmaceutically acceptable salt thereof according to claim 3, wherein R^6 represents nitro group.

5. The benzopyran derivative of the formula (2) or pharmaceutically acceptable salt thereof according to claim 4.

6. The benzopyran derivative or pharmaceutically acceptable salt thereof according to claim 3, wherein R^6 represents $C(O)NH_2$.

7. The benzopyran derivative or pharmaceutically acceptable salt thereof according to claim 3, wherein R^6 represents methyl group.

8. A pharmaceutical characterized by comprising a benzopyran derivative or pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

9. A pharmaceutical for treating arrhythmia characterized by comprising a benzopyran derivative or pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 02/06012

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D311/68 A61K31/353 A61P9/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 12077 A (SQUIBB BRISTOL MYERS CO) 9 March 2000 (2000-03-09) compound B page 81	1
Y	page 1, line 4 - line 7; claim 1	1-9
X	CONNORS, S. P.; ET AL.: "The synthesis and potassium blocking activity of some (4-methanesulfonamidophenoxy)propylamines as potential class III antiarrhythmic agents." J. MED. CHEM., vol. 34, no. 5, 1991, pages 1570-1577, XP001093613 compound 21 page 1576	1-9

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

28 August 2002

Date of mailing of the international search report

20/09/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Seelmann, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 02/06012

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NICOLAOU, K. C.; ET AL.: "Natural Product-like Combinatorial Libraries Based on Privileged Structures." J. AM. CHEM. SOC., vol. 122, no. 41, 2000, pages 9968-9976, XP001096422 compound 19 table 2	1
Y	----- US 5 679 706 A (D ALONZO ALBERT J ET AL) 21 October 1997 (1997-10-21) claims 1,2	1-9
Y	----- EP 0 462 761 A (SQUIBB & SONS INC) 27 December 1991 (1991-12-27) claim 1 -----	1-9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 02/06012

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0012077	A	09-03-2000	AU 5675399 A	21-03-2000
			EP 1109544 A1	27-06-2001
			WO 0012077 A1	09-03-2000
			US 6150356 A	21-11-2000
US 5679706	A	21-10-1997	NONE	
EP 0462761	A	27-12-1991	AU 651105 B2	14-07-1994
			AU 7710291 A	19-12-1991
			CA 2043281 A1	19-12-1991
			CN 1057461 A	01-01-1992
			CS 9101852 A3	15-04-1992
			EP 0462761 A2	27-12-1991
			FI 912931 A	19-12-1991
			HU 58066 A2	28-01-1992
			IE 911948 A1	18-12-1991
			JP 4243852 A	31-08-1992
			MX 26184 A	01-10-1993
			NO 912344 A ,B,	19-12-1991
			PL 290720 A1	23-03-1992
			PL 167832 B1	30-11-1995
			PL 166809 B1	30-06-1995
			PT 98019 A	30-04-1992
			RU 2059635 C1	10-05-1996
			US 5466817 A	14-11-1995
			US 5276168 A	04-01-1994
			ZA 9103923 A	26-02-1992